Common Stock, $0.001 par value per share
- Symbol
- NXTC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 9.01 · 8-K
NextCure, Inc.
NXTCNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Company's remaining approximately 29,864 rentable square feet of leased laboratory and office space located at 8000 Virginia Man…
Company context
NextCure is a biopharmaceutical company focused on managing its legacy clinical and intellectual property assets, pursuing opportunities to maximize those legacy assets, fulfilling ongoing obligations under its existing collaboration and licensing agreements and advancing completion of the Merger with Avere.
Current securities
Registered securities in this filing
NextCure, Inc. · 8-K · Filed 2026-09-03
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01
Entry into a Material Definitive Agreement
On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Company's remaining approximately 29,864 rentable square feet of leased laboratory and office space located at 8000 Virginia Manor Road, Beltsville, Maryland. Pursuant to the Amendment, the Company vacated and surrendered the premises effective August 31, 2026, and the parties agreed to accelerate the expiration of the lease and terminate the Company's future rent obligations effective September 1, 2026, subject to the terms of the Amendment.
In connection with the Amendment, the Company paid a one-time termination fee of approximately $0.8 million and forfeited its security deposit of approximately $39,000.